169 related articles for article (PubMed ID: 17325604)
1. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects.
Tavel JA; Martin JE; Kelly GG; Enama ME; Shen JM; Gomez PL; Andrews CA; Koup RA; Bailer RT; Stein JA; Roederer M; Nabel GJ; Graham BS
J Acquir Immune Defic Syndr; 2007 Apr; 44(5):601-5. PubMed ID: 17325604
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults.
Priddy FH; Brown D; Kublin J; Monahan K; Wright DP; Lalezari J; Santiago S; Marmor M; Lally M; Novak RM; Brown SJ; Kulkarni P; Dubey SA; Kierstead LS; Casimiro DR; Mogg R; DiNubile MJ; Shiver JW; Leavitt RY; Robertson MN; Mehrotra DV; Quirk E;
Clin Infect Dis; 2008 Jun; 46(11):1769-81. PubMed ID: 18433307
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
[TBL] [Abstract][Full Text] [Related]
4. Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial.
Viegas EO; Tembe N; Nilsson C; Meggi B; Maueia C; Augusto O; Stout R; Scarlatti G; Ferrari G; Earl PL; Wahren B; Andersson S; Robb ML; Osman N; Biberfeld G; Jani I; Sandström E
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):193-205. PubMed ID: 28969431
[TBL] [Abstract][Full Text] [Related]
5. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
6. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
7. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
8. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
Frank I; Li SS; Grunenberg N; Overton ET; Robinson ST; Zheng H; Seaton KE; Heptinstall JR; Allen MA; Mayer KH; Culver DA; Keefer MC; Edupuganti S; Pensiero MN; Mehra VL; De Rosa SC; Morris DE; Wang S; Seaman MS; Montefiori DC; Ferrari G; Tomaras GD; Kublin JG; Corey L; Lu S;
Lancet HIV; 2024 May; 11(5):e285-e299. PubMed ID: 38692824
[TBL] [Abstract][Full Text] [Related]
10. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
12. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
Catanzaro AT; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Gu L; Martin JE; Novik L; Chakrabarti BK; Butman BT; Gall JG; King CR; Andrews CA; Sheets R; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
J Infect Dis; 2006 Dec; 194(12):1638-49. PubMed ID: 17109335
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
Catanzaro AT; Roederer M; Koup RA; Bailer RT; Enama ME; Nason MC; Martin JE; Rucker S; Andrews CA; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
Vaccine; 2007 May; 25(20):4085-92. PubMed ID: 17391815
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.
Vasan S; Schlesinger SJ; Huang Y; Hurley A; Lombardo A; Chen Z; Than S; Adesanya P; Bunce C; Boaz M; Boyle R; Sayeed E; Clark L; Dugin D; Schmidt C; Song Y; Seamons L; Dally L; Ho M; Smith C; Markowitz M; Cox J; Gill DK; Gilmour J; Keefer MC; Fast P; Ho DD
PLoS One; 2010 Jan; 5(1):e8617. PubMed ID: 20111582
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.
Ramanathan VD; Kumar M; Mahalingam J; Sathyamoorthy P; Narayanan PR; Solomon S; Panicali D; Chakrabarty S; Cox J; Sayeed E; Ackland J; Verlinde C; Vooijs D; Loughran K; Barin B; Lombardo A; Gilmour J; Stevens G; Smith MS; Tarragona-Fiol T; Hayes P; Kochhar S; Excler JL; Fast P
AIDS Res Hum Retroviruses; 2009 Nov; 25(11):1107-16. PubMed ID: 19943789
[TBL] [Abstract][Full Text] [Related]
16. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
[TBL] [Abstract][Full Text] [Related]
17. Timing of plasmid cytokine (IL-2/Ig) administration affects HIV-1 vaccine immunogenicity in HIV-seronegative subjects.
Baden LR; Blattner WA; Morgan C; Huang Y; Defawe OD; Sobieszczyk ME; Kochar N; Tomaras GD; McElrath MJ; Russell N; Brandariz K; Cardinali M; Graham BS; Barouch DH; Dolin R;
J Infect Dis; 2011 Nov; 204(10):1541-9. PubMed ID: 21940420
[TBL] [Abstract][Full Text] [Related]
18. An HIV-1 clade A/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I/IIa trial in Thai volunteers at low risk of HIV infection.
Hemachandra A; Puls RL; Sirivichayakul S; Kerr S; Thantiworasit P; Ubolyam S; Cooper DA; Emery S; Phanuphak P; Kelleher A; Ruxrungtham K
Hum Vaccin; 2010 Oct; 6(10):835-40. PubMed ID: 20864808
[TBL] [Abstract][Full Text] [Related]
19. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
Kalams SA; Parker S; Jin X; Elizaga M; Metch B; Wang M; Hural J; Lubeck M; Eldridge J; Cardinali M; Blattner WA; Sobieszczyk M; Suriyanon V; Kalichman A; Weiner DB; Baden LR;
PLoS One; 2012; 7(1):e29231. PubMed ID: 22242162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
